Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.
Journal Article (Journal Article)
OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant. DESIGN: Pooled data from 3 multicenter, double-masked, randomized, controlled, phase 2b/3 clinical trials evaluating the safety and efficacy of the 0.59-mg or 2.1-mg FA intravitreal implant or standard therapy were analyzed. RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively. Topical IOP-lowering medication was administered in 74.8% of implanted eyes, and IOP-lowering surgeries, most of which were trabeculectomies (76.2%), were performed on 36.6% of implanted eyes. Intraocular pressure-lowering surgeries were considered a success (postoperative IOP of 6-21 mm Hg with or without additional IOP-lowering medication) in 85.1% of eyes at 1 year. The rate of hypotony (IOP
Full Text
Duke Authors
Cited Authors
- Goldstein, DA; Godfrey, DG; Hall, A; Callanan, DG; Jaffe, GJ; Pearson, PA; Usner, DW; Comstock, TL
Published Date
- November 2007
Published In
Volume / Issue
- 125 / 11
Start / End Page
- 1478 - 1485
PubMed ID
- 17923537
International Standard Serial Number (ISSN)
- 0003-9950
Digital Object Identifier (DOI)
- 10.1001/archopht.125.11.ecs70063
Language
- eng
Conference Location
- United States